Sionna Stock
Sionna Therapeutics is focused on developing treatments for cystic fibrosis through innovative small molecules that target the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its approach aims to fully restore CFTR function, offering potential breakthroughs in treating this genetic disorder.
Founded: 2019
For more Sionna stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Management Team
| Mike Cloonan Chief Executive Officer & President |
| Vanya Sagar Chief People Officer |
| John Macor Ph.D. Chief Scientific Officer |
| Greg Hurlbut Ph.D. Co-Founder & Senior Vice President of Discovery Research |
| Mark Munson Ph.D. Co-Founder & Vice President of Medicinal Chemistry |
| Charlotte McKee MD Chief Medical Officer |
| Elena Ridloff Chief Financial Officer & Head of Corporate Development |
